Amg 133
Amg 133 has been studied in 1 paper since 2021: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Jul 6, 2021: “Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity”.
1 paper studies itUpdated
- 8 trials, none about aging
- 8 of 8 trials sponsored by its developers
Who is developing Amg 133?
1 company: Amgen.
- Companies
- AmgenPhase 3atherosclerotic cardiovascular disease, overweight
Trial sponsors
Company2 trialsPhase 317,856 people
Latest
Expert Opinion on Emerging Drugs
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
ReviewGLP-1 receptor agonists